Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility.
Withdrawal from high levels of progesterone in rodents has been proposed as a model for premenstrual syndrome or postpartum depression. Forced swim test (FST) immobility, used to model depression, was assessed in intact female DBA/2J mice following progesterone withdrawal (PWD) or treatment with the 5alpha-reductase inhibitor finasteride. Following 5 daily progesterone injections (5 mg/kg IP) FST immobility increased only in mice withdrawn for 3 days (p<.05). In another experiment, 3 days of PWD significantly decreased levels of progesterone compared to 0 days of withdrawal, but progesterone levels at 3 days of PWD did not differ from vehicle-treated controls. In a final study, mice received daily injections of progesterone (5 mg/kg IP) for 8 days, with 0 mg/kg, 50 mg/kg, or 100 mg/kg finasteride co-administered for the last three days. Mice that received 100 mg/kg finasteride, but not 50 mg/kg finasteride, displayed increased FST immobility. PWD and finasteride treatment, both of which reduce allopregnanolone levels, were associated with increased FST immobility in female DBA/2J mice. These findings suggest that decreased levels of the GABAergic neurosteroid allopregnanolone contribute to symptoms of PWD. Future studies of PWD may provide information about human conditions that are associated with hormone changes such as premenstrual syndrome or postpartum depression.
Beckley
Ethan H
EH
Oregon Health & Science University, Department of Behavioral Neuroscience, School of Medicine, Mail Code L-470, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, United States. beckleye@ohsu.edu
Finn
Deborah A
DA
D058891:5-alpha Reductase Inhibitors; D000818:Animals; D003863:Depression / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D018120:Finasteride / Q000494:pharmacology; D051379:Mice; D008811:Mice, Inbred DBA; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D011280:Pregnanolone / Q000494:pharmacology; D011374:Progesterone / Q000009:adverse effects* / Q000097:blood / Q000378:metabolism*; D013375:Substance Withdrawal Syndrome / Q000523:psychology*; D013550:Swimming / Q000523:psychology*
D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D011374:Progesterone; D018120:Finasteride; D011280:Pregnanolone